A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy.
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2012
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 01 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2010 Planned end date changed from 1 Jun 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.